Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India
Name:
1110_Sinha_Liposomal-amphoteri ...
Size:
165.4Kb
Format:
PDF
Description:
Main article
Authors
Sinha, Prabhat Kvan Griensven, Johan
Pandey, Krishna
Kumar, Nawin
Verma, Neena
Mahajan, Raman
Kumar, Pankaj
Kumar, Ranjeet
Das, Pradeeb
Mitra, Gaurab
Flevaud, Laurence
Ferreyra, Cecilia
Remartinez, Daniel
Pece, Manuel
Palma, Pedro Pablo
Affiliation
Rajendra Memorial Research Institute of Medical Science, Patna, Bihar; Medecins Sans Frontieres–India, Operational Center Barcelona–Athens, New Delhi, India; Institute of Tropical Medicine, Antwerp, Belgium; Medecins Sans Frontieres, Medical Department, Operational Center Barcelona– Athens, Barcelona, SpainIssue Date
2011-10
Metadata
Show full item recordJournal
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of AmericaAbstract
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV-coinfected patients treated with liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India.Publisher
Oxford University PressPubMed ID
21890763Additional Links
http://cid.oxfordjournals.org/content/53/7/e91.abstractType
ArticleLanguage
enISSN
1537-6591ae974a485f413a2113503eed53cd6c53
10.1093/cid/cir521